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Abstract
Bone is the most common metastatic site for breast cancer. Estrogen-related-receptor alpha (ERRα) has been implicated in
cancer cell invasiveness. Here, we established that ERRα promotes spontaneous metastatic dissemination of breast cancer
cells from primary mammary tumors to the skeleton. We carried out cohort studies, pharmacological inhibition, gain-of-
function analyses in vivo and cellular and molecular studies in vitro to identify new biomarkers in breast cancer metastases.
Meta-analysis of human primary breast tumors revealed that high ERRα expression levels were associated with bone but not
lung metastases. ERRα expression was also detected in circulating tumor cells from metastatic breast cancer patients. ERRα
overexpression in murine 4T1 breast cancer cells promoted spontaneous bone micro-metastases formation when tumor cells
were inoculated orthotopically, whereas lung metastases occurred irrespective of ERRα expression level. In vivo, Rank was
identiﬁed as a target for ERRα. That was conﬁrmed in vitro in Rankl stimulated tumor cell invasion, in mTOR/pS6K
phosphorylation, by transactivation assay, ChIP and bioinformatics analyses. Moreover, pharmacological inhibition of
ERRα reduced primary tumor growth, bone micro-metastases formation and Rank expression in vitro and in vivo.
Transcriptomic studies and meta-analysis conﬁrmed a positive association between metastases and ERRα/RANK in breast
cancer patients and also revealed a positive correlation between ERRα and BRCA1mut carriers. Taken together, our results
reveal a novel ERRα/RANK axis by which ERRα in primary breast cancer promotes early dissemination of cancer cells to
bone. These ﬁndings suggest that ERRα may be a useful therapeutic target to prevent bone metastases.
Introduction
Metastases are the primary cause of death [1] and in breast
cancer (BCa), bone is the most common metastatic site [2].
Bone metastases (BM) detection often occurs in the
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symptomatic stage and when they are diagnosed, the
prognosis for the patient is generally poor and associated
with signiﬁcant morbidity. Unfortunately, current treat-
ments for BM that rely on anti-resorptive agents are only
palliative underlining the need for early detection for early
intervention [3–5].
Nuclear steroid receptors are transcription factors that
comprise both ligand-dependent molecules, such as estro-
gen receptors (ERs) and a large number of so-called orphan
receptors, for which no natural ligands have yet been
identiﬁed [6]. The estrogen-related receptor alpha (ERRα)
shares structural similarities with ERα/β, but it does not
bind estrogens [6]. Indeed, sequence alignment of ERRα
and the ERs reveals a high similarity (68%) in the 66 amino
acids of the DNA-binding domain, but only a moderate
similarity (36%) in the ligand-binding domain [7]. Although
ERRα activity is decreased by synthetic molecules, such as
the inverse-agonists XCT790 or C29, no natural ligand has
yet been found [8, 9].
ERRα is known to regulate the adaptive bioenergetics
response [10]. It is widely expressed in both healthy tissues
and a range of cancerous cells [11–14]. Notably, ERRα-
positive tumors were associated with more invasive disease
and higher risk of recurrences [11–13]. In addition to
angiogenesis, ERRα is mainly linked to tumor cell invasion
[13–15]. ERRα is also highly expressed in skeletal tissues
where it regulates osteoblast/osteoclast physiology [16–19].
In BM, we have reported that overexpression of ERRα in
triple-negative BCa cells and castration-resistant prostate
cancer cells results in either the inhibition or the activation
of tumor cell progression in bone, respectively [20, 21].
Here, we assess whether ERRα in primary breast tumors
regulates the molecular mechanisms that drive BCa cell
homing to bone.
Results
High ERRα protein expression levels in primary
tumors are associated with bone relapse in BCa
patients
We assessed ERRα protein expression levels in primary
tumors from patients of the ABCSG trial 6 cohort, a pro-
spective, randomized clinical study of postmenopausal
patients with hormone receptor-positive early-stage BCa,
treated with tamoxifen-aminoglutethimide and followed for
up to 15 years [22]. Kaplan–Meier analysis showed that
high levels of ERRα protein expression (Fig. 1A, B) cor-
related with lower distant recurrence-free survival (%) (n=
100). After establishing conditions for ERRα detection
using cell lines (Supplementary Fig. S1), we also detected
ERRα expression in circulating tumor cells (CTCs) (Fig.
1C), supporting the hypothesis that ERRα present in CTCs
may be involved in the metastatic process. We then ana-
lyzed the ERRα transcriptional proﬁle in the NKI-295
cohort that includes primary BCa patients with known
location of the ﬁrst distant metastasis site [23] (Supple-
mentary Table S1). Univariate Cox proportional hazard
model analysis indicated that ERRα expression is associated
with metastases-free survival (MFS) and bone metastases
free-survival (BMFS) but not with lung metastases free-
survival (LMFS) (Table 1). Kaplan–Meier curves also
demonstrated that high ERRα expression is correlated with a
decrease in BMFS but not LMFS (Fig. 1D, E). Neither
ERRβ nor ERRγ mRNA expression levels correlated with
MFS, BMFS, or LMFS (Table 1).
ERRα in BCa cells promotes spontaneous bone
micro-metastases formation in vivo
To assess the role of ERRα in the early steps of metastatic
dissemination of BCa, we used the murine 4T1 BCa cell
line, from which cells spontaneously metastasize from pri-
mary tumor to lung and bone [24, 25]. Three independent
4T1 clones overexpressing-ERRα (4T1-ERRα) and two
empty vector controls (4T1-CT) were isolated (Fig. 2Aa). In
parallel, three 4T1-ERRαAF2 clones in which ERRα acts
dominant-negatively, were obtained (Fig. 2Ab) [20, 21].
Analysis of primary breast tumors (Fat-Pad(FP)) indicated
greater tumor progression in mice with 4T1-ERRα-FP
compared to 4T1-CT-FP (Fig. 2Ba–b, C, D), and 4T1-
ERRαAF2-FP tumors (Fig. 2Ba, c, E, F). In agreement with
previous data [26], we found Vegf-a expression increased in
4T1-ERRα-FP tumors (Supplementary Fig. S2), as did
expression of genes implicated in glycolysis and lactate
metabolism (Supplementary Table S2). Culturing cells
collected from crushed bones of mice kept for an additional
21 days post-primary tumor resection and counting colonies
[25] revealed greater tumor cell colonization of bone (TCB)
by 4T1-ERRα-FP (Fig. 2G, Supplementary Fig. S3A), with
higher incidence of dissemination to bone with 4T1-ERRα
cells (77% versus 12% (4T1-CT)) (Fig. 2H) and a higher
number of TCB (Fig. 2I). No signiﬁcant difference was
observed between 4T1-ERRαAF2 cells and 4T1-CT cells
(Fig. 2H, I, Supplementary Fig. S3B). In contrast, histolo-
gical assessment of lung metastases (LM) revealed no dif-
ference in the number or incidence of lung colonies (Fig.
2J–L) or metastases surface amongst all groups (Supple-
mentary Fig. S3C,D), in spite of maintenance of ERRα
overexpression in 4T1-ERRα-LM versus 4T1-CT-LM
(Supplementary Fig. S3E). These pre-clinical data conﬁrm
a correlation between ERRα expression level and BMFS
but not LMFS (Fig. 1D, E; Table 1).
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ERRα regulates Rank expression in BCa cells
To explore the mechanism underlying the ability of ERRα
to promote homing of cancer cells to bone in vivo, we
quantiﬁed in FP-tumors transcriptional expression levels of
several markers known to be involved in the metastatic
process (Fig. 3A; Supplementary Table S2). As expected,
4T1-ERRα-cells undergo epithelial–mesenchymal transition
(EMT) (Supplementary Table S2) [13]. Interestingly,
expression of receptor activator of nuclear factor κ B (Rank)
mRNA was higher in 4T1-ERRα-FP [27–29], whereas no
difference was observed in the mRNA expression of Cxcr4
which had been implicated in lung tropism (Fig. 3A).
Consistent with these data, Rank protein expression was
also higher in 4T1-ERRα-FP (Fig. 3Ba, b). Rank protein
expression was also much higher in 4T1-ERRα cells in
bone metastases (BM) (Fig. 3Ca, c, Cb, d) induced by intra-
arterial (IA) injection of cells, but was barely detectable in
the LM elicited by either cell population (Fig. 3Da, c, Db, d;
Supplementary Fig. S4A,B,C), suggesting a major role of
Rank for BCa cell anchorage and colonization in bone.
Culturing cells collected from crushed bones and lungs
conﬁrmed Rank mRNA up-regulation in 4T1-ERRα-BM
but not in LM (Fig. 3E). The fact that Rank-ligand (Rankl)
expression was signiﬁcantly higher in bone versus lung
(Fig. 3F) further suggests their involvement in BCa cell
colonization of bone but not lung. RANK regulation by
ERRα was conﬁrmed in two human BCa cell lines: the
MCF7 line engineered to overexpress full-length (MCF7-
ERRα) or truncated (MCF7-ERRαAF2) human ERRα
compared to the empty vector control (MCF7-CT) (Fig. 3G,
H) and the MDA-MB-231-B02, known to metastasize only
to bone (Fig. 3I) [20]. Moreover, C29 inhibited Rank
mRNA expression in 4T1 and MCF7 parental cells (Fig.
3J–M) [9, 30]. ERRα and RANK mRNA were also co-
expressed in the human BC-M1 disseminated tumor cell
Fig. 1 ERRα is a bone metastases-associated gene in BCa. A Kaplan–
Meier curves show correlation between high expression of ERRα,
categorized with median value, and distant recurrence-free survival in
patients treated with tamoxifen alone or aminoglutethimide with
tamoxifen (n= 100). B Visualization of ERRα protein expression at
low (a) and high level (b) by IHC on sections of primary breast tumor.
C Representative EpCAM(+), pan-keratin(+) (K-PE), CD45(−) CTCs
and ERRα-AF488(+)/(−) from metastatic BCa patients detected by the
CellSearch® System. DAPI was used for nuclear counter staining. D
Kaplan–Meier curves constructed after segmentation into two groups
on the basis of the median value for ERRα expression show correlation
between high expression of ERRα and lower bone metastases free-
survival (BMFS) in NKI cohort (n= 295, P= 0.01); Low ≤ 50%
quartile; high ≥ 50%. E No correlation was found between high level
of ERRα and lung metastases free-survival (LMFS)
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Fig. 2 ERRα promotes BCa cell homing to bone in vivo. A (a) Three
independent clones (4T1-ERRα 1–3) overexpressing full-length ERRα
and two control clones with empty vector (4T1-CT 1–2) were obtained
after stable transfection of 4T1 cells. ERRα (~54kDa) expression was
assessed by Western blotting and compared to α-tubulin as a protein
loading control showing the ERRα protein band increased in 4T1-
ERRα (1–3) compared to 4T1-CT (1, 2) cells. (b) Three independent
4T1-ERRαAF2 clones (ERRα dominant-negative) and two control
clones (4T1-CT clones 1,2) (empty vector) were obtained and a band
with slightly lower molecular weight, corresponding to the expected
size for truncation of the AF2-AD domain (42aa) (co-activators
binding domain), was present in 4T1-AF2 cells. B 4T1-ERRα (pool of
three clones), 4T1-CT (pool of two clones), or 4T1-ERRαAF2 (pool of
three clones) cells were inoculated into the mammary gland fat pad of
BALB/c mice. Greater tumor expansion was observed in mice with
4T1-ERRα-FP. C–F Weight and volume of tumors dissected at end-
point (n= 10, Mann–Whitney, weight: P= 0.0156; volume: P=
0.0074 for 4T1-ERRα), no difference was observed in mice with 4T1-
ERRαAF2-FP (n= 9). G After resection, animals were kept for
21 days, bones were then crushed and released cells were cultured for
3 weeks. H, I Counting of tumor cells that colonized the bone (TCB)
revealed a high incidence with 4T1-ERRα cells (H) that was asso-
ciated with an increase in TCB number (ANOVA: p < 0.0001 and
Mann–Whitney, P= 0.0083 (n= 9), 262 ± 175 (4T1-ERRα) versus
32 ± 55 (4T1-CT); P= 0.006, 4T1-ERRα versus 4T1-ERRαAF2) (I).
Incidence and TCB number were similar in 4T1-CT and 4T1-
ERRαAF2 cells. J–L Histological assessment of lung metastases (LM)
(J) shows no difference between LM incidence (K) and LM number/
lungs (L) (n= 9). Asterisk represents lung metastases
Table 1 ERRα is a bone
metastases-associated gene in
BCa
Parameter Metastasis free survival Bone metastasis free
survival
Lung metastasis free
survival
P-value HR FDR P-value HR FDR P-value HR FDR
ESRRA 0.008 5.80 0.025 0.003 23.72 0.009 0.215 5.192 0.55
ESRRG 0.08 0.55 0.118 0.56 0.72 0.838 0.366 0.531 0.55
ESRRB 0.39 2.5 0.392 0.94 1.15 0.941 0.673 0.346 0.673
Cohort NKI (n= 295), Univariate Cox proportional hazards model, Wald statistic
Univariate Cox proportional hazard model analysis revealed that ERRα mRNA expression is associated with
metastases free survival (MFS) and bone metastases free survival (BMFS) (n= 295, P= 0.008 and P=
0.001, respectively) while no link was found in lung metastases free-survival (LMFS)
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line and co-stimulated in BC-M1 cells cultured under low
O2 versus normoxia conditions (Fig. 3N) [31].
That Rank stimulation has functional consequences is
supported by the observation that Rankl signiﬁcantly sti-
mulated migration of 4T1-ERRα cells (4T1-ERRα-versus-
4T1-ERRα+Rankl) (Fig. 4A, B). Unexpectedly, the
migratory ability of untreated 4T1-ERRα cells was lower
than that of untreated 4T1-CT cells but this was reversed by
Rankl treatment (Fig. 4B), revealing the high sensitivity of
4T1-ERRα cells to Rankl. Rankl had no effect on migration
of 4T1-ERRαAF2 (4T1-ERRαAF2-versus−4T1-ERRαAF2
+Rankl) (Fig. 4C, D). Consistent with ERRα-Rank
Fig. 3 Correlation between ERRα and Rank expression in BCa cells.
A Real-time PCR performed on mRNA extracted from 4T1 primary
tumors (n= 3 for all conditions) conﬁrmed increased expression of
ERRα in 4T1-ERRα-FP and show increased expression of Rank by
ERRα (ANOVA: P < 0.0001 and unpaired t-test P < 0.0001 for both
ERRα and Rank). Cxcr4 mRNA expression was not altered. B
Increased expression of Rank was visualized by IHC in 4T1-ERRα-FP
(b) compared to 4T1-CT-FP (a) and in bone metastases (BM) (C) after
IA injection of 4T1-ERRα (b, d) compared to 4T1-CT (a, c) cells.
Rank-positive osteoclasts were used as a positive control (see White
arrow). Representative examples of three and two mice for FP tumor
and BM, respectively. D Rank expression was barely detected by IHC
in either 4T1-ERRα-LM (b, d) or 4T1-CT-LM (a, c). Representative
example of n= 2. E, F Real-time RT-PCR was performed on triplicate
samples and normalized against the ribosomal protein gene L32 to
evaluate (E) Rank expression in bone and lung metastases extracted
from 4T1-ERRα versus 4T1-CT tumor-bearing animals (n= 2)
(ANOVA: P < 0.0001, unpaired t-test P= 0.0123 for bone metastases)
and (F) Rankl expression in total normal bone and lung (unpaired t-test
P= 0.0112). G MCF7 clones overexpressing ERRα or ERRαAF2
were obtained after retroviral transfection. ERRα overexpression was
assessed by Western blotting and compared to α-tubulin. H and I Real-
time RT-PCR was performed on triplicate samples and normalized
against the ribosomal protein gene L32 to evaluate RANK expression
in (H) MCF7 clones (ANOVA: P= 0.0135, unpaired t-test P=
0.0041) and (I) MDA-MD231-B02(B02) clones (ANOVA: P=
0.0031, unpaired t-test P= 0.0032). J–M C29 treatment induced a
decrease in Rank expression in both parental 4T1 and MCF7 cells
lines. J, K ERRα protein by Western blot (J) and Rank mRNA by real-
time PCR (K) were inhibited by C29 at 1 μM after 48 h (unpaired t-
test, P= 0.0311) in 4T1 cells. (L, M) Inhibition of ERRα protein (L)
induced by C29 at 1 and 5 μM after 48 h in MCF7 cells is associated
with a decrease of RANK mRNA expression (M) (ANOVA: P=
0.0016, unpaired t-test P= 0.0127 and P= 0.0062). (N) Real-time
PCR was performed on triplicate samples to evaluate ERRα and RANK
expression in the BC-M1 cells under low O2 conditions compared with
normoxia. ERRα and RANK expression was higher under low O2
conditions (unpaired t-test P= 0.0143 and P= 0.0016 for ERRα and
RANK, respectively). All in vitro assays were repeated at least two
times. Data are plotted as mean ± SEM. Bar= 200 μm, T: Tumor, B:
Bone
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signaling, mTOR/S6K phosphorylation was higher in
Rankl-treated 4T1-ERRα cells (Fig. 4E–G) [27]. C29 and
the XCT-790 [8] inhibited Rank mRNA expression in 4T1
parental cells after 24 h treatment and the endogenous
ERRα activity decreased by C29 treatment (Supplementary
Fig. S5AB) suggesting that the effect of ERRα on Rank
expression is direct. This is supported by the ﬁnding that
ERRα transactivates the Rank promoter in 4T1 cells (CT-
versus-ERRαWT) and that this transactivation is dependent
on a functional ERRαAF2 domain (ERRα-versus-ERRαWT
++C29, ERRαWT+XCT790 or ERRαAF2) (Fig. 4H). By
using ChIP-qPCR in BO2-CT and BO2-ERRα cells, we
also show ERRα binding on an ERRE site (TGAAGGTCA)
localized on the human RANK locus (Fig. 4I) (Supple-
mentary Fig. S5C) [20]. ERRα binding to a proximal
(prox), but not to distal (dist) element of its own human
promoter was used as positive and negative controls,
respectively (Fig. 4J) [32, 33].
Fig. 4 Increased migration capacity of BCa cells overexpressing ERRα
after Rankl treatment. A, B Migration was increased in 4T1-ERRα
cells (clones 1–3) after Rankl treatment (50 ng/mL) for 12 h (4T1-
ERRα versus 4T1-ERRα+Rankl: ANOVA: P= 0.0005, unpaired t-
test P= 0.0001). The percentage of migration of 4T1-CT cells (clones
1–2) was unchanged after Rankl treatment (4T1-CT versus 4T1-CT
+Rankl). In the absence of added RankL, migration of 4T1-ERRα
cells was lower than that of 4T1-CT cells (P= 0.0019), but the
opposite was observed after Rankl treatment (P= 0.002: 4T1-CT
+Rankl versus 4T1-ERRα+Rankl). C, D Migration was not modu-
lated in 4T1-ERRαAF2 cells (clones 1–3) after Rankl treatment (50
ng/mL) for 12 h (4T1-ERRαAF2 versus 4T1-ERRαAF2+Rankl). E–G
Rankl signaling was assessed by treating 4T1-ERRα cells (clones1–3)
and 4T1-CT cells (clones1–2) cells with RankL for different times (0,
5, 15, 25 min). Activation of mTOR and S6K was assessed with α-
tubulin as loading control. mTOR and S6K were markedly activated in
4T1-ERRα cells at 5–25 min. H Reporter activity shows the activation
of the Rank promoter activity by ERRα in 4T1 cells (CT versus ERRα-
WT ANOVA: P= 0.0004, unpaired t-test P= 0.0347) that was
blocked by C29 (1 μM) and XCT-790 (1 μM) and which is dependent
on a functional ERRαAF2 domain (cf. ERRα-WT versus ERRα-WT
+C29 or ERRα-WT+XCT790, or ERRαAF2) (P= 0.00275; P=
0.0058; and P= 0.0022, respectively). I ERRα binding to the human
RANK locus was analyzed using ChIP-qPCR in control BO2-CT(CT)
and BO2-ERRα (ERRα) cells (IgG versus ERRα in B02-CT (P=
0.0237) and in B02-ERRα (P= 0.0015)). J ERRα binding to a
proximal (prox), but not to distal (dist) element of its own human
promoter was used as positive (IgG versus ERRα in B02-CT (P=
0.0023) and in B02-ERRα (P < 0.0001)) and negative controls,
respectively. Percent enrichments relative to input of a representative
experiment are shown using anti-ERRα or non-speciﬁc rabbit-IgG
antibody as a negative control. All in vitro assays were repeated two
times. ChIP assay data are representative of two independant ChIP
experiments. Data are plotted as mean ± SEM
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Pharmacological inhibition of ERRα reduces
mammary tumor growth, bone marrow micro-
metastases formation, and RANK expression in vivo
To determine whether inhibition of ERRα abrogates FP-
tumor progression and BCa cell dissemination to bone, mice
were inoculated with 4T1-ERRα cells and treated with the
C29 or vehicle from the time of tumor appearance to tumor
resection. Tumor weight/volume was reduced in 4T1-
ERRα-FP tumor-bearing animals treated with C29 (Fig.
5A–C), as was TCB (Fig. 5D, E) but not LM (Supple-
mentary Fig. S6E), without C29 toxicity (Supplementary
Fig. S6A–D). ERRα and Rank mRNA and protein expres-
sion were reduced in FP-tumors in C29-treated mice (Fig.
5F) (Supplementary Fig. S7A,B).
Bioinformatics analysis reveals an extensive RANK–
ESRRA regulatory interactome
To address further a RANK and ESRRA connection, we
combined bioinformatics analyses of protein interaction
networks and transcriptional regulator databases. We ﬁrst
built an extended network (Supplementary Fig. S8, Table
S3) from public datasets and then deﬁned a minimal net-
work that included well-known ESRRA regulators, e.g.
HDAC8, AIB1, SIRT1, SHP1, and linked ESRRA–RANK
signaling, as exempliﬁed by the presence of TRAFs and c-
SRC (Fig. 5G) [34]. More than half (32 out of 62 proteins)
of the regulators within the network are associated with
extracellular matrix (ECM) regulation, cell adhesion and
migration (see gray boxes, Fig. 5G) and a further half of
these (16 of 32) are proteins encoded by genes that are
potentially directly regulated by ESRRA (Fig. 5H, Sup-
plementary Table S4). By shortest path analysis, we also
identiﬁed two new potential ESRRA–RANK-associated
regulators, such as MEX67 and SP1 (Fig. 5G).
ERRα/RANK are linked in BCa patients who
developed BM
Meta-analysis of the GSE14020 dataset conﬁrmed a posi-
tive association of ERRα and RANK in patients who
developed BM but not in patients who developed lung and
liver metastases (Table 2A) [35]. Moreover, in the Curie
Institute cohort (n= 446), stratiﬁcation of BCa patients into
subtypes revealed a positive correlation between ERRα and
RANK in Triple Negative patients (NNN) and Luminal BCa
patients (HR+ERBB2) but not ERBB2+patients (HR− and
HR+) (Table 2B; Supplementary Fig. S9A,B; Table S5)
[36]. Reinforcing our clinical data obtained in the NKI-294
cohort (Fig. 1D, E), Kaplan–Meier curves demonstrated that
high ERRα expression is correlated with a decrease in
BMFS but not LMFS in the Curie Institute cohort (Fig. 6A,
B). No correlation was observed between ERRα and
RANKL (TNFSF11) (Table 2B). Expression levels of ERRα
and RANK were positively correlated in the TCGA dataset
(Supplementary Fig. S9C) and in primary BCa samples (HR
+ERBB2−) in combined microarray datasets (GSE12276-
GSE2034-GSE2603)(n= 248) (Table 2C; Supplementary
Table S6). The strongest correlation was observed in
patients who had developed only BM (Pearson R= 0.5145)
and no correlation was observed in non-metastatic patients
(No Mets).
ERRα is highly expressed in primary tumors from
BRCA1-mutated carriers
Recently, RANK/RANKL were shown to control BRCA1
mutation-driven mammary tumor formation and progres-
sions [37], prompting us to ask whether ERRα and BRCA1
expression is correlated. Using microarray datasets
(GSE12276-GSE2034-GSE2603), we found a positive
correlation between ERRα and BRCA1 in BCa samples in
patients who had developed both visceral+bone and only
BM, and with BRCA2 expression in patients with metas-
tases at all sites (Table 2C). Since these datasets were not
informative on the BRCA1 and 2 mutations status, we used
the METABRIC cohorts that include 2051 radically resec-
ted primary BCa, where BRCA1mut or 2mut were identiﬁed.
ERRα expression level was higher in BRCA1mut carriers but
not BRCA2mut-carriers compared to those with no mutations
(Fig. 6C). By bioinformatics, our minimal network was
structured over three main protein hubs (ESRRA, ESR, and
BRCA1) (Fig. 5G). Systematic shortest path analysis
revealed that ESRRA could control RANK and
BRAC1 signaling (Fig. 6D) and, more speciﬁcally, BRCA1
through SRC1, AIB1, SP1, RIP140, and ESR which are
ESRRA regulators [13, 14, 38, 39]. ESRRA may also
directly regulate BRCA1 (with ﬁve potential ESRRA-
binding sites) (Fig. 6F) and ESR, AIB1, SRC1, MEX67,
and SP1 (Fig. 6F).
Discussion
Our ﬁndings indicate that ERRα is expressed in CTCs and
promotes BCa cell homing to bone. The identiﬁcation of
Rank as an ERRα-regulated gene in our pre-clinical 4T1 cell
model and ERRα/RANK-positive association in BCa patient
cohorts provide new mechanistic insights into ERRα-regu-
lated pathways mediating early BCa cell colonization of
bone.
Elevated ERRα expression has been associated with
tumor aggressiveness [13]. The fact that we have observed
ERRα expression in CTCs of BCa metastatic patients and
documented changes in BCa cell migration with changes
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in ERRα activity strengthens the notion that ERRα may
be involved into CTCs survival and metastases.
We found that a high level of ERRα was associated with
bone but not LM in our mouse experimental model of
spontaneous metastatic BCa and in two independent (n=
740) BCa patient cohorts, suggesting that ERRα/RANK
expression in primary tumors may be a predictive marker of
BM occurrence in BCa patients. With respect to bone
colonization, our identiﬁcation of RANK as a new ERRα-
regulated gene is notable. RANK, the cognate receptor of
RANKL, was described as being predictive of poor prog-
nosis in patients with BM but not in patients with visceral
metastases [28, 29, 40]. One explanation comes from evi-
dence that RANKL is a chemoattractant that is more highly
expressed in bone than lung, thus promoting bone coloni-
zation (Fig. 3F): RANKL produced by osteoblasts has been
shown to attract RANK-expressing cancer cells and induce
their migration in the bone microenvironment [41]. This
mechanism has been observed not only in BCa but also in
other cancers [29] indicating that RANKL is one of the
important “soil” factors that promote BCa-Rank+cell bone
colonization. Additionally, knockdown of Rank expression
in metastatic BCa-reduced BM indicating that RANK is
required for BCa migratory response toward RANKL-
Fig. 5 Pharmacological inhibition of ERRα. A 4T1-ERRα (clones 1–
3) cells were inoculated into the FP of the mammary gland of BALB/c
mice and mice were treated with C29 (10 mg/kg) for 10 days from the
time of tumor appearance to tumor resection (day 14). C29 (C29-
Tumor-FP) (d–f) decreased tumor expansion compared to tumor
growth in vehicle treated mice (a–c). B, C Weight and volume of
tumors dissected at endpoint (n= 9, unpaired t-test, weight: P= 0.014;
Mann and Whitney: volume: P= 0.019). D, E After tumor resection,
animals were kept for an additional 21 days, bones were then crushed
and released cells were cultured for 3 weeks. C29 treatment (Dd–f; E)
decreased TCB number compared Veh (Da–c; E) (n= 5, 142 ± 138
versus 416 ± 138, unpaired t-test, P= 0.035). F Real-time PCR
performed on RNA extracted from C29 (C29-Tumor-FP) versus
vehicle-treated (Veh-Tumor-FP) mice (n= 3, unpaired t-test P= 0.004
for ERRα and P= 0.0032 for Rank) conﬁrmed a decrease in the
expression of ERRα and Rank in treated animals. G By bioinformatics
analysis, a protein interaction and transcriptional regulation network
was built. Potential new regulators, including MEX67 and SP1, were
identiﬁed through systematic shortest path deﬁnition of cross-talks (see
black bold line). 32 out of 62 regulatory proteins are associated with
ECM regulation, cell adhesion and migration (see gray boxes). H
GTRD database analysis indicated that 16 of the 32 regulatory proteins
are encoded by genes that could be directly regulated by ESRRA
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expressing bone cells in vivo [41, 42]. This, together with
the fact that the 4T1-CT cells that colonized bone highly
express Rank while Rank was barely detectable in lung (Fig.
3Ca, Da), strongly suggests that RANK is a prerequisite
factor for cancer cell colonization of bone. Consistent with
RANK–RANKL signaling [27], EMT, mTOR/S6K, and
cell migration were stimulated in 4T1-ERRα.
RANKL has recently been linked to mitochondrial mass
in osteoclasts [17, 43], and glucose uptake and glycolysis
with increased PGC1α, GLUT1, LDHA, and VEGF
expression in osteoblasts resembling the Warburg effect
[44, 45]. ERRα and Pgc1α, which is up-regulated in 4T1-
ERRα-FP, are known to play a major role in coordinating
oncometabolic programs [13]. Interestingly, these genes
which are all direct targets of ERRα, were all up-regulated
in vivo in 4T1-ERRα-FP, suggesting that RANKL–RANK
may also participate in cancer cell metabolic reprogram-
ming to meet the rapid energy requirement for survival and
metastases. Interestingly, by bioinformatic, we identiﬁed
MEX67 and SP1 two potential ESRRA-RANK-associated
Table 2 Correlation between
ERRα and Rank expression in
BCa patients
A
GSE14020
n= 65
All
ESRRA
65
Bone Mets
ESRRA
18
Lung Mets
ESRRA
20
Liver Mets
ESRRA
5
Pearson-correlation coefﬁcient
TNFRSF11A (RANK) R= 0.510 R= 0.515 R= 0.457 R= 0.009
P < 0.0001 P= 0.0287 P= 0.0504(NS) P= 0.884(NS)
B
Curie n= 446 All
ESRRA
446
NNN
ESRRA
68
HR-ERBB2
+ESRRA
42
HR+ERBB2-
ESRRA
285
HR+ERBB2
+ESRRA
51
Spearman-correlation
coefﬁcient
TNFRSF11A (RANK) R= 0.318 R= 0.299 R= 0.25 R= 0.303 R= 0.203
P < 0.0000001 P= 0.013 P= 0.11(NS) P= 0.00000099 P= 0.15(NS)
TNFSF11 (RANKL) R= 0.054 R= 0.146 R= 0.058 R=−0.001 R=−0.017
P= 0.25(NS) P= 0.23
(NS)
P= 0.71(NS) P= 0.99(NS) P= 0.90(NS)
C
GSE12276
2034-2603
n= 248
All
ESRRA
248
No Mets
ESRRA
121
Visceral+bone
ESRRA
53
Bone only
ESRRA
74
Pearson-correlation coefﬁcient
TNFRSF11A (RANK) R= 0.4063 R= 0.1050 R= 0.4667 R= 0.5145
P < 0.0001 P= 0.2517(NS) P= 0.0005 P < 0.0001
BRCA1 R= 0.2949 R= 0.1470 R= 0.332 R= 0.2846
P < 0.0001 P= 0.1075(NS) P= 0.0152 P= 0.0140
BRCA2 R= 0.5113 R= 0.3559 R= 0.425 R= 0.5026
P < 0.0001 P < 0.0001 P= 0.0015 P < 0.0001
A Meta-analysis of the public dataset GSE14020 (n= 65) revealed correlation between ERRα and RANK in
all tumors and in patients with bone but not lung or liver metastases. B Meta-analysis of the Curie BCa
cohorts (n= 446) revealed correlation between ERRα and RANK (TNFRSF11A) mRNA expression in the
total tumor population, in the triple negative group and in the luminal group (HR+ERBB2−). No correlation
was found in ERBB2+patients (HR− and HR+) or with RANKL (TNFSF11). C Meta-analysis of public
datasets (GSE12276, GSE2034, and GSE2603) (n= 248) revealed correlation between ERRα and RANK,
BRCA1 and BRCA2 expression levels in all tumors, in patients with visceral and bone metastases or only
bone metastases. Correlation scores were calculated using the Spearman correlation coefﬁcient for the Curie
cohort and the Pearson correlation coefﬁcient for GSE14020 and GSE12276-GSE2034-GSE2603. P-values
< 0.05 were considered statistically signiﬁcant
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regulators that had been detected in invasive ductal BCa and
as an ERRα transcription control factor-coregulator,
respectively [46, 47] (Expression-Atlas-EMBL—EBI).
Moreover, the RANK/RANKL axis is a critical regulator of
BRCA1-mutation-driven BCa and anti-RANKL therapy is
now proposed as a preventive strategy for women carrying
BRCA1 mutations [37, 48]. We found a signiﬁcant corre-
lation between high ERRα and BRCA1mut in BRCA1mut
carriers, implying that ERRα may participate directly in the
RANKL/RANK control of progenitor cell expansion and
tumorigenesis in inherited BCa and/or via the modulation of
BRCA1 (by, e.g., the ERRα coregulators, SRC-1, AIB1,
and RIP140) (Fig. 6D–F). The presence of ESR in our
shortest path analysis also reinforces the link
between ERRα/ERα in BCa. Similarly to the suggestion
that inhibition of the RANKL/RANK axis may be a ther-
apeutic target for BRCA1mut carriers, inhibition of an
upstream RANK regulator, ERRα, may also
constitute a useful new therapeutic approach for these
patients. In conclusion, we report for the ﬁrst time a RANK/
ERRα axis in BCa that contributes new mechanistic
understanding of the negative outcome associated with
ERRα in BCa.
Materials and methods
Ethics approval
BALB/c female mice were purchased from Janvier and
handled according to the French Ministerial Decree no. 87–
848 of 19 October 1987. Experimental protocols were
approved by the Institutional Animal Care and Use Com-
mittee at the Université-Lyon1 (France)(CEEA-55 Comité
d’Ethique en Expérimentation Animale-DR2014-44-
DR2015-28). Studies involving human primary specimens
were carried out according to the principles embodied in the
Declaration of Helsinki.
Fig. 6 A Kaplan–Meier curves constructed after segmentation into two
groups on the basis of the median value for ERRα expression show
correlation between high expression of ERRα and lower bone
metastases-free survival (BMFS) in Curie BCa cohorts (n= 446, P=
0.04); Low ≤ 50% quartile; high ≥ 50%. B No correlation was found
between high expression of ERRα and lung metastases free-survival
(LMFS). C Meta-analysis of the METABRIC cohorts that include
2051 radically resected primary BCa, where BRCA1 and 2 mutations
were identiﬁed, revealed correlation between high ERRα and BRCA1
mutation (Mann–Whitney P= 0.02). No link was found between
ERRα expression and BRCA2 mutation. D Analysis of our minimal
network (Fig. 5G) showed that ESRRA could control RANK and
BRAC1 signaling and, more speciﬁcally, (E) BRCA1 through SRC1,
AIB1, SP1, RIP140 and ESR. (F) GTRD database analysis indicated
that ESRRA may directly regulate BRCA1; ESRRA-binding sites are
also present in ESR, AIB1, SRC1, MEX67, and SP1
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Study on BCa patient primary tumor specimens
Immunohistochemistry (IHC) was performed on formalin-
ﬁxed parafﬁn-embedded (FFPE) tumor tissue sections (n=
100) from the Austrian-Breast and Colorectal-Cancer-Study
Group (ABCSG) Trial-6 [22]. For IHC, FFPE tumor tissue
and a mouse monoclonal anti-ERRα antibody (1/50) (sc-
65715, Santa-Cruz) were used. Sections were incubated
with HRP-conjugated anti-mouse (Dako), stained using
3,3′-diaminobenzidine (Dako) and Mayer’s hematoxylin
(Merck). ERRα immunostaining was assessed by the H-
score method [49].
Samples of 446 unilateral invasive primary breast tumors
excised from women managed at Institut-Curie-Hôpital-
René-Huguenin (France) for which grading information was
available (Supplementary Table S5) were analyzed [36, 50].
The mean age of the patients was 61.8 years, and the
median follow-up was 103.1 months. Since 2007, patients
have signed inform consent. This study was approved by
the review board and ethics committee of the institute. A
tumor sample was considered suitable for our study if the
proportion of tumor cells exceeded 70% [36]. Real-time-
PCR was performed using speciﬁc primers (Supplementary
Table S7) for human housekeeping gene TBP (TATA-box-
binding protein), ERRα, RANK, and RANKL (ABI-Prism-
7900 sequence-detection-system) (Perkin-Elmer-Applied-
Biosystems, CA), and the PE-Biosystems analysis software
according to the manufacturer’s manuals [36]. Results were
expressed as fold differences equal to 2−ΔΔCt.
Detection of ERRα in CTC
For ERRα detection in CTC detection, patients after signed
inform consent, were recruited at the Cancer Institute of
Montpellier in 2017 (Bioethic-committee D-RCB 2015-
A00119-40). We ﬁrst performed experiments by adding 200
BCa cells (SKBR3 and MDA-MB-231) to 7.5 mL of PBS.
To mimic blood of BCa patients, we spiked 200 BCa cells
in 7.5 mL of blood from healthy donors. Tumor cells were
detected by using the CellSearch® system (Silicon-Biosys-
tem, Menarini) with the CellSearch CTC Kit. This FDA-
cleared semiautomatic system contains a ferroﬂuid-based
capture reagent targeting all EpCAM-positive cells, which
could be further identiﬁed as CTCs by a pan-keratin (CK8-
18-19) and nuclear staining. Contaminating leukocytes were
excluded by CD45 staining. For ERRα detection, we used
the fourth channel of the CellSearch® and the anti-human
ERRα/NR3B1-A488-conjugated polyclonal antibody
(Novus, USA) (25 μg/mL). The corresponding Rabbit IgG-
Isotype control (Alexa-Fluor®488) (Novus) was used at the
same ﬁnal concentration. Blood of three metastatic BCa
patients were analyzed for the presence of CTCs over-
expressing ERRα.
Meta-analysis of ESSRA expression
For the BCa cohorts “NKI” (n= 295) [23] and “METAB-
RIC” (n= 2051) [51], the genomic and transcriptomic data
were obtained through the cBioPortal Web resource (http://
cbioportal.org). All statistical calculations were performed
using PASW Statistics (version 18.0; SPSS Inc., Chicago,
IL) and a two-sided unpaired Student's t-test. By using of
the receiver operating characteristic method, we determine
whether ESRRA, ESRRB, and ESRRG expression levels
were able to deﬁne low-metastases and high-metastases risk
populations.
For correlation analysis, published datasets were down-
loaded from the Gene-Expression-Omnibus including pri-
mary tumors, bone, lung, and liver metastases (GSE14020)
(n= 65) [35] and primary tumor, no-metastases, visceral
+bone or only BM (GSE12276-GSE2034-GSE2603) (n=
248) [52–54]. Z-scores were obtained by normalizing data
were log2 transformed and calculating by subtracting the
population mean from individual expression values for each
gene and then dividing the difference by the population
standard deviation. Correlation scores were calculated using
the Pearson-correlation-coefﬁcient. P-values < 0.05 were
considered statistically signiﬁcant. Statistical signiﬁcance
was determined by GraphPad Prism v5.02 using the two-
sided Student's t-test.
Cell lines, transfection, and immunoblotting
Human MCF7 (year 2012) and mouse 4T1(year 2012) BCa
cell lines were obtained from the American Type Culture
Collection. 4T1, MDA-MB231-B02 [20] and MCF7 were
cultured in DMEM or RPMI-1640 (Life-Technologies)
medium, respectively, supplemented with 10% fetal bovine
serum (FBS, Perbio) and 1% penicillin/streptomycin (Invi-
trogen) at 37 °C in a 5% CO2 incubator. The human BC-M1
(Vimentin/CK5-positive, CK8/18-negative, HER2) cell line
(generous gift from the Dr. K. Pantel lab) was obtained
from a bone marrow aspirate of a BCa patient with no
clinical signs of distant metastases at the time of the primary
tumor resection [31, 55]. BC-M1 cells were cultured in
complete RPMI-1640 medium (Life-Technologies) supple-
mented with 10% FBS, 200 U/mL penicillin/streptomycin
(Life-Technologies), insulin–selenium–transferrin (IST)
(Gibco, France), 50 ng/mL of epidermal growth factor
(EGF), and 10 ng/mL of human basic-ﬁbroblasts growth
factor (bFGF) (Miltenyi-Biotec, France) at 37 °C in a 5%
CO2, low (10% of O2), or normoxic (21% of O2) conditions.
Total mRNA was extracted using the RNAeasy Mini Kit
(Qiagen, Courtabeuf).
Murine and human ERRα cDNA (ERRα) and the
dominant-negative co-activator domain AF2 (AF2) mutant
were obtained previously [20, 21, 56]. pSRα-ERRαWT and
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pSRα-ERRαAF2 or empty vector constructs were trans-
fected into parental 4T1 cells and cultured for 4 weeks in
puromycin (2 μg/mL) (Life-Technologies). For MCF7
clones, a mix containing 1.5 μg Retroviral pLPCX-Huma-
nERRαWT, pLPCX-HumanERRαAF2, or empty vector
and 0.5 µg pCMV-VSV-G envelope vector (Cell-Biolabs)
were transfected by calcium phosphate precipitation (Cal-
Phos-mammalian-Transfection-Kit,Clontech), according to
the manufacturer’s instruction with selection in puromycin
(2 μg/mL) (Life-Technologies) for 3 weeks.
Parental 4T1 and MCF7 cells were treated with the
ERRα inverse-agonist C29 (AGVdiscovery, France) at 1
and 1–5 μM, respectively, for 24 and 48 h [9, 30, 33, 57].
XCT790 (Sigma) was also used at 1 μM [8]. DMSO was
used as vehicle. For Rankl studies, 4T1-CT (two clones),
4T1-ERRα (three clones) were plated at 5 × 105 cells/well in
complete medium. The next day, cells were starved for 24 h
and then treated with Rankl (50 ng/mL) (R&D) for different
times (0–5–15–25 min). Protein extraction and immuno-
blotting was performed as described [20], using antibodies
against ERRα (Abcam-EPR46Y) (1:400), mTOR and
pmTOR (Ser2481) (Cell-Signaling) (1:1000), S6K and
pS6K (Thr389) (Cell-Signaling) (1:1000), or α-tubulin
(Cell-Signaling) (1:1000) as protein-loading control [20,
21]. The experiments were done in triplicated and repeated
two times.
Animal studies
BALB/c female mice (6 weeks), were housed in barrier
conditions under isolated laminar ﬂow hoods. Mice bearing
tumor xenografts were monitored for established signs of
distress and were humanely euthanized. Tumor fat pad (FP)
experiments were performed (n= 10 for each groups) using
the 4T1-CT (two clones), 4T1-ERRα (three clones), or 4T1-
AF2 (three clones) cell lines (105 cells in 10 μL of PBS)
injected into FP of the fourth mammary gland of mice as
described [58]. Brieﬂy, primary tumors were resected
2 weeks after cell injection and tumor weight and size were
measured. For spontaneous metastases dissemination stu-
dies (lungs (macro-metastases), bone (micro-metastases)),
mice were followed after resection for an additional 3 weeks
at which time they were sacriﬁced. Lungs were collected for
histological analysis or crushed (C29 experiment). Hind
limbs were removed and crushed. Cells released from lungs
(C29 experiment) and bone were incubated at 37 °C in the
presence of DMEM supplemented with FBS and 6-
Thioguanine (10 μg/mL) for 3 weeks before tumor cells
that colonized the bone (TCB) and lung colonies were
stained by using Crystal Violet and counted.
FP experiments were performed using 4T1-ERRα cells
(three clones) (105 cells in 10 μL of PBS). When primary
tumors reached ~30 mm3, mice were randomized (n= 10),
treated every 2 days for 10 days by intra-peritoneal injection
with vehicle (DMSO 10%, 30% PEG) or C29 (10 mg/kg)
[9, 57], then prepared and analyzed as above. Bone lesion
experiments were performed using 4T1-CT (two clones)
and 4T1-ERRα cells (three clones) cells (105 cells in 100 μL
of PBS) injected intra-arterially (IA). After 2 weeks, bones
and lungs were collected for histological analysis (n= 2).
Some hind limbs and lungs were removed and crushed for
mRNA extraction.
IHC on mice FP-tumor sections
5 μm parafﬁn sections were incubated overnight with
RANK(1/50)(Abcam-64C1385), or Vegf-a(1/50)(Abcam-
EP1176Y) or ERRα antibody (1/50)(Santa-Cruz-V19) [20],
followed by incubation with horseradish peroxidase (HRP)-
conjugated anti-mouse or anti-rabbit (Dako) antibodies for
1 h and staining with 3,3′-diaminobenzidine (Dako) and
Mayer’s hematoxylin (Merck).
Cell migration assay
Migration assays were done with the HTS FluoroBlokTM-
Multiwell-Insert-system (8 μm corning) as described [20].
After 12 h of starvation, 4T1-CT (two clones), 4T1-ERRα
(three clones), and 4T1-ERRαAF2 (three clones)(5 × 104
cells) were plated in the upper chambers and the chemoat-
tractant (0.5%FBS) with or without Rankl (50 ng/mL)
(R&D) in the lower chambers. After 12 h at 37 °C in 5%
CO2 incubator, cells that had migrated through the ﬁlters
were ﬁxed, stained with DAPI (Life-Technologies) and
counted. All experiments (n= 2) were run in triplicate,
migration was expressed in % of migration/wells.
Transactivation assay
4T1 cells (106 cells/well in six-well plates) were transfected
with a mouse Rank promoter-driven Gaussia-Luciferase-
reporter plasmid (pEZX-PG04 RankLuc:−1450/+31)
(Genecopoeia) and TurboFect Transfection Reagent
according to the reverse transfection protocol (Thermo-
Scientiﬁc). 4T1 cells were cotransfected with plasmids
expressing ERRα-WT or mutated ERRαAF2. The ratio of
DNA/Turbofect was 4 µg/6 µL. After overnight incubation,
transfection medium was replaced with fresh medium
containing DMSO 0.1% or XCT790(1 µM) or C29(1 µM).
Medium aliquots were withdrawn at 48 h for measuring
Gaussia Luciferase with the Secrete-Pair™ Gaussia
Luciferase-Assay Kit in Buffer GL-S (Genecopoeia). The
experiments were done in triplicated and repeated two
times.
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Real time-PCR
Total RNA was extracted with Trizol-reagent (Life-Tech-
nologies) and 2 μg was reverse-transcribed using
SuperscriptTM-II (Life-Technologies) [21]. Real-time PCR
was performed on a Mastercycler-ep-Realplex (Eppendorf)
with primers speciﬁc to human and mouse genes (Supple-
mentary Table S7) using Quantifast-SYBR-Green (Life-
Technologies) according to the manufacturer’s instructions
[21]. The ribosomal protein L32 gene was used as control
and relative results expressed as fold differences equal to 2-
ΔΔCt.
Protein–Protein interaction network reconstruction
and analysis
We reconstructed the protein–protein interaction network
with BIOGRID (release 3.4.160) protein–protein interaction
data from Homo sapiens with Proteomics-Standard-Initia-
tive-Common-QUery-InterfaCe (PSICQUIC) retrieval
(05292018) and CytoScape environment [34]. A custom
approach was used to deﬁne a protein interactome of the
following proteins: ESRRA-ESR-RIP140-SRC1-SRC2-
SRC3-PGC1A-PGC1B-TRAF6-TRAF5-TRAF2-PDK1-
GLUT1-LDHA-TNFRSF11A. The resulting interactome
encompasses more than 300 proteins (so called “Extended
Network”). To determine the connectors between ESR,
RANK, BRCA1, and ESRRA, a custom approach com-
bining shortest path and connectivity degree analysis was
applied to determine a “Minimal Network” acknowledging
connections that may support ESRRA signaling. We over-
laid information from Gene-Ontology-consortium to pin-
point proteins that are already known to be involved in the
regulation of ECM assembly and degradation, as well as
cellular adhesion and migration (GO-IDs: 1903053-
0022617-012715-0007155-0016477). Generated network
maps by using CyNetShare (cynetshare.ucsd.edu) can be
up-loaded for public access (https://doi.org/10.18119/
N9PC7F) (Supplementary Fig. S8) [59].
Determination of ESRRA-mediated transcriptional
regulation
We determined the proteins encoded by human genes under
the control of ESRRA and the number of regulatory sites
within these genes using the GTRD ChIP-seq database
(http://gtrd.biouml.org/) [60].
Chromatine immunoprecipitation (ChIP)
ChIP assays were performed as previously described [61]
from MDA-MB231-B02-CT and -ERRα cells [20] using
either a monoclonal rabbit anti-ERRα (13826) (Cell-
Signaling) or a control rabbit IgG(2729) antibody (Cell-
Signaling). The immune-precipitated genomic DNA was
puriﬁed using NucleoSpin Clean-up colums (Macherey-
Nagel, Germany) and analyzed by qPCR. Quantiﬁcation of
ChIP enrichment was calculated relative to input values.
Distal and proximal elements of ERRα gene were used as
negative and positive controls, respectively (Supplementary
Table S7) [32, 33].
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software (San Diego, USA). Data were analyzed statisti-
cally by the non-parametric Mann–Whitney U-test or
unpaired t-test for in vivo studies (n= 10 mice for each
group (bioStaTGV), unblinding studies). In vitro assays
were repeated at least two times and performed on triplicate
samples. Data were analyzed using ANOVA and Student's
t-test to assess the differences between groups. MFS,
LMFS, and BMFS were determined as the interval
between diagnosis and detection of the ﬁrst metastases.
Survival distributions were estimated by the Kaplan–Meier
method, and the signiﬁcance of differences between survi-
val rates was ascertained using the log-rank test. Univariate
and multivariable analyses using Cox proportional
hazards models were used to assess the independent con-
tribution of each variable to organ-speciﬁc MFS. All
data are presented as means ± SEM with variance were
similar between the groups. Statistical tests, differences
were considered signiﬁcant at conﬁdence levels >95% (p <
0.05).
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